TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$127.99 USD
+3.55 (2.85%)
Updated May 3, 2024 04:00 PM ET
After-Market: $127.80 -0.19 (-0.15%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TMDX 127.99 +3.55(2.85%)
Will TMDX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TMDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TMDX
Will TransMedics (TMDX) Gain on Rising Earnings Estimates?
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
TMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out?
Is TransMedics (TMDX) a Buy as Wall Street Analysts Look Optimistic?
Other News for TMDX
TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
10 Health Care Stocks Whale Activity In Today's Session
TransMedics Group (TMDX): A Smart Investment or a Value Trap? An In-Depth Exploration
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
12 Health Care Stocks Moving In Wednesday's Intraday Session